Dawn L. Hershman, MD, MS, Columbia University Medical Center, discusses preventing chemotherapy-induced peripheral neuropathy (CIPN) in diabetic patients with cancer.
Dawn L. Hershman, MD, MS, Columbia University Medical Center, discusses preventing chemotherapy-induced peripheral neuropathy (CIPN) in diabetic patients with cancer.
Clinicians treating patients who already have diabetes-related neuropathy need to be careful in prescribing certain chemotherapy drugs that may worsen the neuropathy, especially in the palliative care setting where there may not be much benefit. For patients who may see a marginal benefit with chemotherapy, perhaps clinicians would consider prescribing docetaxel instead of paclitaxel to reduce CIPN risk.
Nursing Perspectives on Managing Toxicities With ADCs in Metastatic Gastric and Breast Cancers
September 1st 2022In this episode of "The Vitals," Sarah Donahue, MPH, NP, AOCNP; Jamie Carroll, APRN, CNP, MSN; Theresa Wicklin Gillespie, PhD, MA, RN, FAAN; and Elizabeth Prechtel-Dunphy, DNP, RN, ANP-BC, AOCN, exchange clinical pearls for treating patients receiving antibody-drug conjugates.
ERBT Before Ra-223 May Not Increase Hematological Toxicity in mCRPC
January 26th 2024Patients with metastatic castration-resistant prostate cancer who were previously treated with external beam radiation therapy before radium-223 did not experience an increase in hematological toxicity compared with the overall population.
Side Effect Education Critical for Patients With Cervical Cancer Treated With Pembrolizumab
January 22nd 2024With pembrolizumab plus chemoradiotherapy now approved by the FDA for patients with advanced cervical cancer, one expert explained the importance of “making sure that patients know what to look for and what to report.”